Search Results - "MOEBIUS, Hans J"

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial by Gauthier, Serge, Prof, Feldman, Howard H, Prof, Schneider, Lon S, Prof, Wilcock, Gordon K, Prof, Frisoni, Giovanni B, Prof, Hardlund, Jiri H, MD, Moebius, Hans J, MD, Bentham, Peter, MBChB, Kook, Karin A, PhD, Wischik, Damon J, PhD, Schelter, Bjoern O, Prof, Davis, Charles S, PhD, Staff, Roger T, PhD, Bracoud, Luc, MSc, Shamsi, Kohkan, MD, Storey, John M D, Prof, Harrington, Charles R, PhD, Wischik, Claude M, Prof

“…Summary Background Leuco-methylthioninium bis(hydromethanesulfonate; LMTM), a stable reduced form of the methylthioninium moiety, acts as a selective inhibitor…”
Get full text

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia by Keefe, Richard S E, Meltzer, Herbert A, Dgetluck, Nancy, Gawryl, Maria, Koenig, Gerhard, Moebius, Hans J, Lombardo, Ilise, Hilt, Dana C

“…Encenicline is a novel, selective α7 nicotinic acetylcholine receptor agonist in development for treating cognitive impairment in schizophrenia and Alzheimer's…”
Get full text

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial by Wilcock, Gordon K, Gauthier, Serge, Frisoni, Giovanni B, Jia, Jianping, Hardlund, Jiri H, Moebius, Hans J, Bentham, Peter, Kook, Karin A, Schelter, Bjoern O, Wischik, Damon J, Davis, Charles S, Staff, Roger T, Vuksanovic, Vesna, Ahearn, Trevor, Bracoud, Luc, Shamsi, Kohkan, Marek, Ken, Seibyl, John, Riedel, Gernot, Storey, John M D, Harrington, Charles R, Wischik, Claude M

“…LMTM is being developed as a treatment for AD based on inhibition of tau aggregation. To examine the efficacy of LMTM as monotherapy in non-randomized cohort…”
Get more information

Predictive Power of Cognitive Biomarkers in Neurodegenerative Disease Drug Development: Utility of the P300 Event-Related Potential by Olichney, John, Xia, Jiangyi, Church, Kevin J., Moebius, Hans J.

“…Neurodegenerative diseases, such as Alzheimer’s disease (AD), and their associated deterioration of cognitive function are common causes of disability. The…”
Get full text

Phase II Trial of the Sigma-1 Receptor Agonist Cutamesine (SA4503) for Recovery Enhancement After Acute Ischemic Stroke by URFER, Roman, MOEBIUS, Hans J, SKOLOUDIK, David, SANTAMARINA, Estevo, SATO, Wakao, MITA, Shiro, MUIR, Keith W

“…The σ-1 receptor (Sig-1R) agonist cutamesine (SA4503) enhanced functional recovery after experimental stroke with a treatment initiation window of 48 hours and…”
Get full text

Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia by Johnston, Jewel L., Reda, Sherif M., Setti, Sharay E., Taylor, Robert W., Berthiaume, Andrée-Anne, Walker, William E., Wu, Wei, Moebius, Hans J., Church, Kevin J.

“…Summary All types of dementia, including Alzheimer’s disease, are debilitating neurodegenerative conditions marked by compromised cognitive function for which…”
Get full text

Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease by Reda, Sherif M., Setti, Sharay E., Berthiaume, Andrée-Anne, Wu, Wei, Taylor, Robert W., Johnston, Jewel L., Stein, Liana R., Moebius, Hans J., Church, Kevin J.

“…Positive modulation of hepatocyte growth factor (HGF) signaling may represent a promising therapeutic strategy for Alzheimer's disease (AD) based on its…”
Get full text

ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS by Berthiaume, Andrée-Anne, Reda, Sherif M, Kleist, Kayla N, Setti, Sharay E, Wu, Wei, Johnston, Jewel L, Taylor, Robert W, Stein, Liana R, Moebius, Hans J, Church, Kevin J

“…Amyotrophic lateral sclerosis (ALS), a progressive and fatal neurodegenerative disorder, primarily affects the motor neurons of the brain and spinal cord. Like…”
Get full text

The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor (HGF/MET) Positive Modulators by Moebius, Hans J, Church, Kevin J

“…An estimated 6.5 million Americans aged 65 years or older have Alzheimer's disease (AD), which will grow to 13.8 million Americans by 2060. Despite the growing…”
Get more information

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an alpha 7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia by Keefe, Richard SE, Meltzer, Herbert A, Dgetluck, Nancy, Gawryl, Maria, Koenig, Gerhard, Moebius, Hans J, Lombardo, Ilise, Hilt, Dana C

“…Encenicline is a novel, selective alpha 7 nicotinic acetylcholine receptor agonist in development for treating cognitive impairment in schizophrenia and…”
Get full text

Diagnostic criteria for apathy in neurocognitive disorders by Miller, David S., Robert, Philippe, Ereshefsky, Larry, Adler, Lawrence, Bateman, Daniel, Cummings, Jeff, DeKosky, Steven T., Fischer, Corinne E., Husain, Masud, Ismail, Zahinoor, Jaeger, Judith, Lerner, Alan J., Li, Abby, Lyketsos, Constantine G., Manera, Valeria, Mintzer, Jacobo, Moebius, Hans J., Mortby, Moyra, Meulien, Didier, Pollentier, Stephane, Porsteinsson, Anton, Rasmussen, Jill, Rosenberg, Paul B., Ruthirakuhan, Myuri T., Sano, Mary, Zucchero Sarracini, Carla, Lanctôt, Krista L.

“…Introduction Apathy is common in neurocognitive disorders (NCD) but NCD‐specific diagnostic criteria are needed. Methods The International Society for CNS…”
Get full text

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial by Hua, Xue, Church, Kevin, Walker, William, L'Hostis, Philippe, Viardot, Geoffrey, Danjou, Philippe, Hendrix, Suzanne, Moebius, Hans J

“…Fosgonimeton (ATH-1017) is being developed as a first-in-class regenerative therapy for people with Alzheimer's disease (AD) and dementia; potentially…”
Get more information

Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia by Shiells, Helen, Schelter, Bjoern O, Bentham, Peter, Baddeley, Thomas C, Rubino, Christopher M, Ganesan, Harish, Hammel, Jeffrey, Vuksanovic, Vesna, Staff, Roger T, Murray, Alison D, Bracoud, Luc, Wischik, Damon J, Riedel, Gernot, Gauthier, Serge, Jia, Jianping, Moebius, Hans J, Hardlund, Jiri, Kipps, Christopher M, Kook, Karin, Storey, John M D, Harrington, Charles R, Wischik, Claude M

“…Hydromethylthionine is a potent inhibitor of pathological aggregation of tau and TDP-43 proteins. To compare hydromethylthionine treatment effects at two doses…”
Get more information

A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus by Suckfüll, Markus, Althaus, Michael, Ellers-Lenz, Barbara, Gebauer, Alexander, Görtelmeyer, Roman, Jastreboff, Pawel J, Moebius, Hans J, Rosenberg, Tanja, Russ, Hermann, Wirth, Yvonne, Krueger, Hagen

“…Neramexane is a new substance that exhibits antagonistic properties at α9α10 cholinergic nicotinic receptors and N-methyl-D-aspartate receptors, suggesting…”
Get full text

Clusterization of Behavioral and Psychological Symptoms of Dementia as Assessed by Neuropsychiatric Inventory: A Case Against the Use of Principal Component Analysis by Galankin, Timofey L, Bespalov, Anton Y, Moebius, Hans Y

“…The term Behavioral and Psychological Symptoms of Dementia (BPSD) covers a group of phenomenologically and medically distinct symptoms that rarely occur in…”
Get more information

Quantitative EEG as a translational measure for the assessment of ATH‐1017 neurophysiological changes in mild‐to‐moderate Alzheimer’s disease by Hua, Xue, Church, Kevin, Walker, William, L'Hostis, Philippe, Ereshefsky, Larry, Kawas, Leen, Moebius, Hans J.

“…Background Athira Pharma, Inc. is developing a new class of blood‐brain barrier (BBB)‐penetrant small molecule drugs aimed at activating the neurotrophic…”
Get full text

Biomarker analyses from the phase 2, randomized, placebo‐controlled ACT‐AD and open‐label extension clinical trials of fosgonimeton in patients with mild‐to‐moderate Alzheimer’s disease by Moebius, Hans J., Ooi, Kai‐Bin C., Hale, Michael D., Setti, Sharay E., Kleist, Kayla N., Pan, Josh, Church, Kevin J., Sabbagh, Marwan

“…Background Despite the multifactorial nature of Alzheimer’s disease (AD), research has primarily targeted amyloid‐beta and tau; other approaches are needed…”
Get full text

ACT‐AD: Fosgonimeton in mild‐to‐moderate Alzheimer’s disease – first results of a randomized, placebo‐controlled, 26‐week Phase 2 proof‐of‐concept trial by Moebius, Hans J., Bernick, Charles B., Winner, Paul, Maalouf, Joyce, Ooi, Kai‐Bin, Dickson, Samuel P., Hendrix, Suzanne B., Church, Kevin, Olichney, John M.

“…Background Fosgonimeton (ATH‐1017) is a positive modulator of HGF/MET, a key neurotrophic pathway impaired in Alzheimer’s disease (AD). Neuronal MET expression…”
Get full text

Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders by Bawa, Kritleen Kaur, Sankhe, Krushnaa, Md, Daniel Bateman, Cummings, Jeffrey L., Ereshefsky, Larry, Husain, Masud, Ismail, Zahinoor, Manera, Valeria, Mintzer, Jacobo, Moebius, Hans J., Mortby, Moyra E, Porsteinsson, Anton P., Robert, Philippe, Miller, David S., Lanctôt, Krista L.

“…Background Diagnostic criteria for apathy (DCA) in neurocognitive disorders were developed in 2021. As next steps, we assessed whether commonly‐used validated…”
Get full text

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an [alpha]7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia by Keefe, Richard Se, Meltzer, Herbert A, Dgetluck, Nancy, Gawryl, Maria, Koenig, Gerhard, Moebius, Hans J, Lombardo, Ilise, Hilt, Dana C

“…Encenicline is a novel, selective α7 nicotinic acetylcholine receptor agonist in development for treating cognitive impairment in schizophrenia and Alzheimer's…”
Get full text